Rapport Therapeutics, Inc. Common Stock Stock Prediction and Forecast [RAPP]

AI-generated source summary

The analysis focuses on Rapport Therapeutics, stock RAPP. Since September 5th, 2025, the system ranks RAPP as a sell candidate with a score of -4.563. A 3-month trend suggests a potential 34.71% change, with returns ranging from 34.71% to 68.18%. The 12-month analysis forecasts a negative change of -37.75%, varying from -94.88% to -17.62%. On Friday, September 5th, the stock closed at $14.36, down 6.45%. The stock fluctuated 12.32% during the day. A buy signal from the 3-month Moving Average Convergence Divergence (MACD) exists, negative signals are also present. RAPP holds sell signals from both short and long-term Moving Averages. Resistance levels are at $15.79 and $15.14. Insider trading shows recent sells, which may have early warning indicating that the stock should be followed more closely. RAPP finds support at $12.66 and $12.04. Stock's volume rose on falling prices on Friday.The general rating for RAPP is a sell

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   06 Sept 2025, 03:46 UTC

   The analyst published the original source item.

2. First prediction resolved

   08 Sept 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   08 Sept 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:13 UTC

   Tahlil Plus began monitoring the extracted predictions.